An evaluation of the best practices and barriers for the Nagasaki acute myocardial infarction secondary prevention clinical pathway
This study identified the perceived best practices and barriers for the NASP. This knowledge should be considered when expanding the NASP to other institutions across Japan.
Authors
- Satoshi Ikeda (ORCID: https://orcid.org/0000-0001-8163-8038)
- Koji Maemura (ORCID: https://orcid.org/0000-0002-4945-675X)
- T. Akiyama
- Katsuya Mori (ORCID: https://orcid.org/0009-0004-5000-0196)
- Masaya Kurobe (ORCID: https://orcid.org/0009-0007-0784-562X)
- Akihito Uda (ORCID: https://orcid.org/0000-0002-4880-1195)
- Yosuke Yamanaka (ORCID: https://orcid.org/0000-0003-1882-6364)
- Ayumi Morishita
- Yuta Ishikawa
Institutions
- Novartis (Switzerland) (CH)
- IQVIA (United Kingdom) (GB)
- Novartis (Japan) (JP)
- IQ Solutions (US)
- Nagasaki University Hospital (JP)
- Nagasaki University (JP)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1080/13696998.2024.2395164
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 1.13